Chemed

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, with revenue of $673.3M exceeding the $665.0M estimate. Adjusted EPS reached $6.06, significantly outperforming the $5.60 expectation. The outperformance was primarily driven by the VITAS segment, where a sharp reduction in Medicare Cap billing limitations (+455 bps impact) and a 6.1% increase in days-of-care offset continued softness in Roto-Rooter's water restoration business. A massive share repurchase program ($287.5M in H1) further accelerated EPS growth relative to net income.